Home > Insider Trading > Filing (0001209191-11-015182)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1100962	Endo Pharmaceuticals Holdings Inc	ENDP	Pharmaceutical Preparations (2834)	134022871

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1328288	P. Ivan Gergel	C/O Endo Pharmaceuticals 100 Endo Boulevard Chadds Ford PA 19317	Evp, Research & Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value, $.01 Per Share	Acquisiton	2011-02-28	30,603	$19.93	30,603	No	4	M	Direct
Common Stock, Par Value, $.01 Per Share	Disposition	2011-03-02	30,603	$35.77	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2007 Stock Incentive Plan Options	Disposition	2011-02-28	30,603	$0.00	30,603	$19.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
91,809		2019-02-26	No	4	M	Direct

Footnotes

On December 3, 2010, Dr. Gergel placed 91,809 of the shares underlying his stock options into a 10b5-1 pre-set selling program until December 31, 2011 (the "Gergel Pre-Set Selling Program"). The options exercised and the shares sold here were sold pursuant to the Gergel Pre-Set Selling Program, which leaves 61,206 shares (underlying options) in the Gergel Pre-Set Selling Program.
This represents the average price at which Dr. Gergel's common shares were sold on on March 2, 2011.
Dr. Gergel's stock options that were granted under the 2007 Stock Incentive Plan on February 26, 2009, are generally exercisable 25% per year on each of February 26, 2010, February 26, 2011, February 26, 2012 and February 26, 2013. The 30,603 stock options that were exercised now are those that became exercisable on February 26, 2011.
These securities were granted to Dr. Gergel in consideration of his services as the Executive Vice President, Research & Development of Endo Pharmaceuticals Holdings Inc.